Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Saint-Herblain , March 26, 2024 – Valneva SE , a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and immunogenicity of VLA1601,...

Related Keywords

Israel ,Mexico ,Japan ,Hong Kong ,South Korea ,Norway ,Australia ,United States ,Canada ,Liechtenstein ,New Zealand ,Singapore ,Iceland ,France ,Republic Of Korea ,America ,Japanese ,French ,Juan Carlos Jaramillo ,Joshua Drumm ,Dynavax Technologies Corporation ,Exchange Commission ,World Health Organization ,Access To Advanced Health Institute ,Global Communications ,Tropical Disease Priority Review Voucher Program ,Pfizer ,Euronext Paris ,Drug Administration ,Tropical Disease Priority Review Voucher ,Advanced Health Institute ,Chief Medical Officer ,Southeast Asia ,Pacific Islands ,South America ,Prescribing Information ,European Investor ,Global Investor Relations ,Disease Priority Review Voucher Program ,Emergent Biosolutions ,Valneva Report Positive Phase ,Their Vaccine Candidate Against ,Zika Virus ,Markets ,